Scancell Holdings plc (AIM: SCLP), a developer of immunotherapies for the treatment of cancer, on Monday reported positive data from the ongoing SCOPE trial for SCIB1 in combination with ipilimumab and nivolumab in advanced melanoma patients.

At the 25-week milestone, 80% of the 25 patients in cohort 1 showed progression-free survival (PFS), with 20% achieving complete response (CR). The disease control rate (DCR) reached 84%, and the objective response rate (ORR) was 72%. These results compare favourably to the double checkpoint inhibitors alone, where PFS was 65%, CR was 16%, DCR was 58%, and ORR was 48%.

Cohort 1 has enrolled 42 out of 43 patients, with all expected to reach week 25 by H1 2025. Additionally, cohorts 2 and 3 are progressing, focusing on SCIB1 combined with pembrolizumab and the next-generation iSCIB1+ with ipilimumab and nivolumab, respectively. The data will inform the selection of the optimal vaccine for future phase 2/3 trials.

Scancell is advancing its immunotherapy pipeline, leveraging platforms like ImmunoBody and AvidiMab to target cancer with novel vaccines and monoclonal antibodies. The SCOPE trial aims to establish SCIB1 and iSCIB1+ as effective additions to standard checkpoint inhibitor therapies.